Their income is higher every quarter by over 100% and will continue to grow. They will soon be able to charge more for their product as the need grows and that will increase their profit margin. They are continuing to sign more contracts and customer chains!
Bottom line:
GROWTH
and for the biotech sector, this is a rare occurrence.